Frovatriptan
From Wikipedia, the free encyclopedia
 |
|
|
Frovatriptan
|
|
| Systematic (IUPAC) name | |
| 6-methylamino-6,7,8,9-tetrahydro -5H-carbazole-3-carboxamide |
|
| Identifiers | |
| CAS number | |
| ATC code | N02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C14H17N3O |
| Mol. mass | 243.304 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 20-30% |
| Metabolism | Hepatic |
| Half life | 26 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral |
Frovatriptan (Frova®) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1] Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets.
Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than for other triptans.
Frovatriptan is available only by prescription in the United States, where a secondary New Drug Approval (sNDA) was filed in July 2006[2] and which is currently pending.[3]
[edit] External links
- Frova (manufacturer's website)
- Frovatriptan (patient information)
- Frovatriptan Succinate (patient information)
Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
